WO2010014613A3 - Treating various disorders using trkb agonists - Google Patents

Treating various disorders using trkb agonists Download PDF

Info

Publication number
WO2010014613A3
WO2010014613A3 PCT/US2009/051966 US2009051966W WO2010014613A3 WO 2010014613 A3 WO2010014613 A3 WO 2010014613A3 US 2009051966 W US2009051966 W US 2009051966W WO 2010014613 A3 WO2010014613 A3 WO 2010014613A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
effective amount
therapeutically effective
administering
compounds
Prior art date
Application number
PCT/US2009/051966
Other languages
French (fr)
Other versions
WO2010014613A2 (en
Inventor
Keqiang Ye
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Priority to CA2732266A priority Critical patent/CA2732266A1/en
Priority to EP09803483.8A priority patent/EP2318010A4/en
Priority to US13/056,377 priority patent/US8203009B2/en
Priority to CN2009801372174A priority patent/CN102159215B/en
Publication of WO2010014613A2 publication Critical patent/WO2010014613A2/en
Publication of WO2010014613A3 publication Critical patent/WO2010014613A3/en
Priority to US13/479,653 priority patent/US8609870B2/en
Priority to US13/727,977 priority patent/US20130131157A1/en
Priority to US15/092,133 priority patent/US20160213691A1/en
Priority to US15/492,414 priority patent/US20170216319A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods and compounds for the treatment of disorders including neurologic, neuropsychiatric, and metabolic disorders are provided. For example, a method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of the described compounds. A further method of promoting neuroprotection in a subject is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of the described compounds.
PCT/US2009/051966 2008-07-28 2009-07-28 Treating various disorders using trkb agonists WO2010014613A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2732266A CA2732266A1 (en) 2008-07-28 2009-07-28 Treating various disorders using trkb agonists
EP09803483.8A EP2318010A4 (en) 2008-07-28 2009-07-28 Treating various disorders using trkb agonists
US13/056,377 US8203009B2 (en) 2008-07-28 2009-07-28 Neurotrophic activity of deoxygedunin
CN2009801372174A CN102159215B (en) 2008-07-28 2009-07-28 Treating various disorders using TrkB agonists
US13/479,653 US8609870B2 (en) 2008-07-28 2012-05-24 Treating various disorders using TrkB agonists
US13/727,977 US20130131157A1 (en) 2008-07-28 2012-12-27 Treating various disorders using trkb agonists
US15/092,133 US20160213691A1 (en) 2008-07-28 2016-04-06 Treating Various Disorders Using TrkB Agonists
US15/492,414 US20170216319A1 (en) 2008-07-28 2017-04-20 Treating Various Disorders Using TrkB Agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8411708P 2008-07-28 2008-07-28
US61/084,117 2008-07-28
US11890708P 2008-12-01 2008-12-01
US61/118,907 2008-12-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/056,377 A-371-Of-International US8203009B2 (en) 2008-07-28 2009-07-28 Neurotrophic activity of deoxygedunin
US13/479,653 Division US8609870B2 (en) 2008-07-28 2012-05-24 Treating various disorders using TrkB agonists

Publications (2)

Publication Number Publication Date
WO2010014613A2 WO2010014613A2 (en) 2010-02-04
WO2010014613A3 true WO2010014613A3 (en) 2010-04-22

Family

ID=41610931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/051966 WO2010014613A2 (en) 2008-07-28 2009-07-28 Treating various disorders using trkb agonists

Country Status (5)

Country Link
US (5) US8203009B2 (en)
EP (1) EP2318010A4 (en)
CN (1) CN102159215B (en)
CA (1) CA2732266A1 (en)
WO (1) WO2010014613A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318010A4 (en) 2008-07-28 2014-05-21 Univ Emory Treating various disorders using trkb agonists
EP2579870B1 (en) 2010-06-09 2018-02-14 Emory University Trkb agonists and methods of use
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014018741A1 (en) 2012-07-27 2014-01-30 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
CN102901815B (en) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 Enzyme-linked immuno sorbent assay (ELISA) kit for detecting site activity of 816/817th site tyrosine of tropomyosin-related kinase B (TrkB) receptor and method using same
JP2015078310A (en) * 2013-10-17 2015-04-23 三菱レイヨン株式会社 Prepreg
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178179A1 (en) * 2005-09-12 2007-08-02 Vijai Lakshmi Pharmaceutical composition for treatment of diabetes and dyslipidemia
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
WO2008058269A2 (en) * 2006-11-09 2008-05-15 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988920A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
EP2318010A4 (en) 2008-07-28 2014-05-21 Univ Emory Treating various disorders using trkb agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178179A1 (en) * 2005-09-12 2007-08-02 Vijai Lakshmi Pharmaceutical composition for treatment of diabetes and dyslipidemia
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
WO2008058269A2 (en) * 2006-11-09 2008-05-15 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2318010A4 *
WANG, Y. L. ET AL., BRAIN RESEARCH, vol. 1210, 19 May 2008 (2008-05-19), pages 84 - 91, XP022648083 *

Also Published As

Publication number Publication date
CN102159215A (en) 2011-08-17
EP2318010A2 (en) 2011-05-11
US20170216319A1 (en) 2017-08-03
US20120277222A1 (en) 2012-11-01
CN102159215B (en) 2013-07-17
CA2732266A1 (en) 2010-02-04
US8203009B2 (en) 2012-06-19
US8609870B2 (en) 2013-12-17
US20130131157A1 (en) 2013-05-23
US20160213691A1 (en) 2016-07-28
WO2010014613A2 (en) 2010-02-04
US20110144096A1 (en) 2011-06-16
EP2318010A4 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
WO2010014613A3 (en) Treating various disorders using trkb agonists
WO2010011836A3 (en) Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
TWI374141B (en) Spiro-oxindole compounds and their uses as therapeutic agents
CL2013001558A1 (en) The use of s1p receptor modulating or agonist compounds to decrease heart rate by approximately 2 beats / minute; method to reduce, prevent or limit a negative chronotropic effect; a pharmaceutical kit
JP2008513516A5 (en)
MY147442A (en) Imidazoquinolines as lipid kinase inhibitors
RU2009136592A (en) THERAPEUTIC AGENTS
Mourão et al. Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones
WO2007092416A3 (en) Melanin concentrating hormone receptor-1 antagonists
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NO20080317L (en) Substituted tetrahydro-1H-Pyrido [4,3-B] Indoles such as serotonin receptor agonists and antagonists
NZ602754A (en) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
WO2010114824A8 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
MA30821B1 (en) PYRAZOLINE DERIVATIVES USEFUL AS ANTAGONISTS OF MINERALOCORTICOID RECEPTORS
EP1948161A4 (en) Method for preventing and treating conditions mediated by ppar using macelignan
AR062886A1 (en) TIAZOL PIRAZOLOPIRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT
EA200901159A1 (en) DERIVATIVES 3-CYANO-4- (4-PHENYLIPIPERIDIN-1-IL) Pyridine-2-OH
EA200901160A1 (en) DERIVATIVES 3-CYANO-4- (4-TETRAGIDROPIRANPHENYL) PYRIDIN-2-IT
RU2007107494A (en) Tricyclic derivatives of indenopyrrole as modulators of serotinin receptors, a pharmaceutical composition based on them, and a method for treating diseases, and / or non-trivial necrosis.
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
KR102151578B1 (en) Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
BRPI0814382A2 (en) COMPOUND, USE OF COMPOUND, AND PHARMACEUTICAL COMPOSITION
JP2008508365A5 (en)
PL1828151T3 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980137217.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803483

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2732266

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009803483

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13056377

Country of ref document: US